RGTPQ — RegenETP, Share News
0.000.00%
Last trade - 00:00FinancialsHighly SpeculativeMicro Cap
- $1.14m
- -$5.21m
- $0.81m
PolarityTE rises on fourth U.S. patent
Brief: Polarityte Announces Allowance Of Fourth U.S. Patent
Brief: Polarityte Announces U.S. FDA Approval Of IND For Pivotal Phase 3 Study Of Skinte® For Chronic Cutaneous Ulcer
Brief: PolarityTE Announces Submission Of Complete Response To FDA's Clinical Hold Correspondence For SkinTE Investigational New Drug Application
PolarityTE Inc reports results for the quarter ended in September - Earnings Summary
Brief: PolarityTE Reports Third Quarter Financial Results
PolarityTE Inc expected to post a loss of 12 cents a share - Earnings Preview
PolarityTE tumbles as FDA puts skin repair product on clinical hold
Brief: PolarityTE Provides Update On U.S. FDA Investigational New Drug Application For SkinTE
PolarityTE Inc reports results for the quarter ended in June - Earnings Summary
Brief: Polarityte Reports Second Quarter Financial Results And Provides Business Update
PolarityTE Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: PolarityTE Says SkinTE Met Primary And Secondary Endpoints In Final Analysis
Brief: PolarityTE Submits IND Application For SkinTE In Chronic Cutaneous Ulcers
PolarityTE rises on new Chinese patent for skin treatment technology
Brief: PolarityTE Receives Notice Of Allowance For Chinese Patent
PolarityTE Inc reports results for the quarter ended in March - Earnings Summary
PolarityTE: Falls on plans to stop commercial sales of skin treatment
Brief: PolarityTE Reports Qtrly Gaap Loss Per Share $0.24